Albumin plus blood thinner for severe cirrhosis after hospital recovery
Treatments studied
Part of Digestive system clinical trials.
This Phase 2 trial tests whether giving albumin together with enoxaparin (a blood thinner) can improve outcomes for people hospitalized with decompensated cirrhosis who are at high risk. It may help your recovery after certain serious liver-related complications and reduce the chance of poor outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be age 18 to 80.
- Have decompensated cirrhosis and were admitted to the hospital for a serious liver-related problem (like fluid buildup, confusion, GI bleeding, infection, or a mix).
- Have a CLIF-C AD score of 45 or higher at admission or during your hospital stay.
- Be recovering from the acute problem and expected to be discharged within the next 72 hours.
- Be able to start and follow the study right after this hospital episode, including giving written consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies two ways of giving albumin (a protein given through an IV) to people with cirrhosis who also have a sudden kidney injury from sepsis. The goal is to see which method—tailored to each patient or a fixed dose—is safer and works better for kidney recovery.
This trial tests whether the blood thinner apixaban can help prevent early-stage cirrhosis from worsening. You may be eligible if you have compensated (stable) cirrhosis due to alcohol and have signs of portal hypertension.
This Phase 4 study looks at how clotting measurements relate to bleeding risk in people with liver cirrhosis who need a planned liver procedure. The study may help doctors understand what coagulation results mean when doing these procedures safely.
This trial tests whether a pill (dabigatran) or a daily injection (enoxaparin) is better at preventing new blood clots in the liver vein for people with cirrhosis. Both are blood thinners, and the study wants to see which one is safer and more effective.
This early study tests whether the blood thinner pills rivaroxaban and apixaban can be used safely in people with liver cirrhosis that is not too severe. It may help doctors understand the safest way to prevent or treat blood clots in this group.
This trial tests whether a personalized long-term albumin (a blood protein medicine) can help people with advanced liver scarring who have fluid in the belly (ascites). It compares the personalized albumin approach to standard care to see if it improves outcomes over time.
Hear when a new Liver Cirrhosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.